Amgen, Sandoz trial over Enbrel patents likely delayed-and a biosimilar could be, too

A patent fight has already delayed Sandoz’ biosimilar version of Amgen’s anti-inflammatory blockbuster Enbrel. And now, it looks as if Sandoz will have to wait a little longer for a clear shot at the launch.

Read More

From drug pricing and ‘biosimilars’ to opioids and culture – a wrap and podcast from the J.P. Morgan Healthcare Conference – San Francisco Business Times

It could be weeks or a year before the deals that biotech executives and financiers started at last week’s 36th J.P. Morgan Healthcare Conference come to fruition. But here’s a quick wrap – and a BioFlash podcast – of tidbits from Bay Area companies: BAGGING OPIOIDS McKesson Corp.

Read More